Case Studies

Challenge A company had developed a technology for overcoming solubility issues in drug formulations and was planning to develop a small number of 505 (b)(2) candidate molecules. The client had...

Project Challenge: A European biotech company was developing next-generation ADC payloads with at least as good intracellular cytotoxicity properties as other payloads used in ADCs, but with a much...

Challenge: A public, multi-national pharmaceutical company historically focused on producing generics (including branded), active pharmaceuticals ingredients, biologics, and over the counter...

Challenge: An early-stage biotechnology company with several assets in pre-clinical development for CNS diseases wanted to supplement its internal pipeline with external innovation. The company...

Challenge A European clinical-stage biopharma company was developing a recombinant protein for multiple immune-driven indications and required support in shaping its future business strategy....

Challenge: Our client was advising principal investors on a possible transaction to cover the development and commercialization of a product targeting chemotherapy-induced anemia (CIA). Alacrita was...

Challenge: A UK investment company was considering leading an investment round in a UK-based platform technology company utilizing induced pluripotent stem cells (iPSCs) in disease models as R&D...

Challenge: An early-stage biotechnology startup company reached out to Alacrita for critical support of its two lead AAV-delivered gene therapy programs. As a virtual company, the client needed...

Challenge A European company developing novel antiviral drugs urgently needed an experienced pharmaceutical physician to work as an interim CMO, as the predecessor was about to move into a leadership...

Challenge A European investor was refocusing its investment efforts and considering targeting the oncology cell therapy space. It had a particular interest in tumor infiltrating lymphocytes (TILs)...

Challenge A pharma investor client joined a European animal health company and asked Alacrita to conduct a strategic review, in the light of urgent business needs. The entire sector had been through...

Challenge Our client was a privately-held US biotech company developing a proprietary platform technology for in vivo expression of DNA coding for a therapeutic antibody or protein. The approach...